Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.
Level 4 - case-series / case-control
Cross-sectional comparative mechanistic study in human cohorts
PubMed 12697741 · doi:10.1172/JCI17215
What was done
Researchers isolated bone marrow mononuclear cells from 36 women divided into three groups of 12: premenopausal (Group A), early postmenopausal (Group B), and age-matched estrogen-treated postmenopausal (Group C). Using two-color flow cytometry with an osteoprotegerin-Fc probe (OPG-Fc-FITC), they quantified cell-surface RANKL expression on preosteoblastic marrow stromal cells (BAP+), T lymphocytes (CD3+), and B lymphocytes (CD20+). Surface RANKL levels were correlated with circulating 17beta-estradiol and biochemical bone resorption markers (serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen).
What was found
Surface RANKL concentration per cell (measured by fluorescence intensity) was 2- to 3-fold higher in untreated postmenopausal women (Group B) compared to both premenopausal women (Group A) and estrogen-treated postmenopausal women (Group C) across marrow stromal cells, T cells, B cells, and total RANKL-expressing cells. Across all participants, RANKL expression in all three cell types correlated positively with serum and urinary bone resorption markers, and total RANKL expression correlated inversely with serum 17beta-estradiol. The abstract did not report exact correlation coefficients, p-values, or confidence intervals.
Why it matters
This study provides direct evidence in human bone marrow that estrogen deficiency increases cell-surface RANKL on stromal and immune cells, identifying a cellular mechanism for postmenopausal bone loss and its suppression by estrogen therapy.
Limits
The study is limited by a small sample size (n = 12 per group) and a cross-sectional design that cannot establish within-subject causality over time. Measurements were performed ex vivo on aspirated bone marrow cells, and the abstract omits exact statistical parameters (such as p-values and confidence intervals).
Cited by
- supports Estrogen is osteoprotective, so postmenopausal decreases in estrogen increase bone resorption and osteoporosis risk.